Prasco Laboratories, a privately held pharmaceutical company specializes in providing product lifecycle management solutions, has expanded its supply agreement with Shionogi Inc, the US-based group company of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company.
Under the terms of the agreement, Prasco will market and distribute the authorized generic version of Sular (Nisoldipine) extended release tablets in 8.5 mg, 17 mg, and 34 mg strengths in the US under the Prasco label.
The financial terms of the agreement were not disclosed.
Nisoldipine extended release tablets are AB-rated, therapeutically equivalent and substitutable as permitted by state law for the brand Sular.
“Prasco’s authorized generic of Sular will bring the quality and reliable supply of the brand drug while also offering additional choices and savings to consumers and patients,” said David Vucurevich R.Ph., president and COO of Prasco. “By selecting an authorized generic strategy, pharmaceutical companies can obtain a lifecycle management solution that provides patients, pharmacists and physicians with the therapeutically equivalent product and generic savings.”
Sular is a registered trademark of Shionogi Inc.
Prasco is the privately held pharmaceutical company specializes in providing product lifecycle management solutions such as authorized generics to brand pharmaceutical companies. Prasco Authorized Generics provide patients with the identical brand drug experience, at a price that competes with generics.